IL-35+ DCs and interacting T cells enrich P35 and Ebi3 expression, and mice vaccinated using IL-35+ DCs exhibit enhanced tumor growth and reductions in T cells within the TME, consistent with the ability of this cytokine to constrain intratumoral immune responses (73, 74). This evidence concerns the gene IL12A and neoplasm.